×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CELC – celcuity inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CELC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/18
09:30 am
celc
Columbia Flexible Capital Income Fund Q4 2025 Commentary [Seeking Alpha]
Low
Report
Columbia Flexible Capital Income Fund Q4 2025 Commentary [Seeking Alpha]
3/18
08:00 am
celc
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Medium
Report
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
3/17
08:01 am
celc
Celcuity (CELC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.
Low
Report
Celcuity (CELC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.
3/15
05:19 pm
celc
What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders [Yahoo! Finance]
Low
Report
What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders [Yahoo! Finance]
3/14
08:12 pm
celc
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference [Yahoo! Finance]
Low
Report
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference [Yahoo! Finance]
3/13
11:17 am
celc
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug [Yahoo! Finance]
Low
Report
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug [Yahoo! Finance]
3/12
11:07 am
celc
Celcuity (CELC) had its "outperform" rating reaffirmed by Wolfe Research.
Low
Report
Celcuity (CELC) had its "outperform" rating reaffirmed by Wolfe Research.
3/10
04:23 pm
celc
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/9
07:17 pm
celc
Form SCHEDULE 13D/A Celcuity Inc. Filed by: Growth Equity Opportunities 18 VGE, LLC
Medium
Report
Form SCHEDULE 13D/A Celcuity Inc. Filed by: Growth Equity Opportunities 18 VGE, LLC
2/17
04:01 pm
celc
Form SCHEDULE 13G/A Celcuity Inc. Filed by: PERCEPTIVE ADVISORS LLC
Low
Report
Form SCHEDULE 13G/A Celcuity Inc. Filed by: PERCEPTIVE ADVISORS LLC
2/17
09:03 am
celc
Form SCHEDULE 13G Celcuity Inc. Filed by: Avoro Capital Advisors LLC
Low
Report
Form SCHEDULE 13G Celcuity Inc. Filed by: Avoro Capital Advisors LLC
2/13
04:29 pm
celc
Form 4 Celcuity Inc. For: Feb 11 Filed by: ROMP CHARLES R
Medium
Report
Form 4 Celcuity Inc. For: Feb 11 Filed by: ROMP CHARLES R
2/13
04:28 pm
celc
Form 3 Celcuity Inc. For: Feb 11 Filed by: ROMP CHARLES R
Medium
Report
Form 3 Celcuity Inc. For: Feb 11 Filed by: ROMP CHARLES R
2/12
05:01 pm
celc
Form SCHEDULE 13G/A Celcuity Inc. Filed by: Soleus Private Equity Fund II, L.P.
Low
Report
Form SCHEDULE 13G/A Celcuity Inc. Filed by: Soleus Private Equity Fund II, L.P.
2/12
04:31 pm
celc
Form 8-K Celcuity Inc. For: Feb 11
Low
Report
Form 8-K Celcuity Inc. For: Feb 11
1/29
04:32 pm
celc
Form 4 Celcuity Inc. For: Jan 27 Filed by: Dalvey David
Low
Report
Form 4 Celcuity Inc. For: Jan 27 Filed by: Dalvey David
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
7.9%
4/23 Celcuity Inc. Schedules Release of First Quarter 2020 Financial Results and Conference Call 7.6%
5/8 Celcuity Inc (NASDAQ: CELC) was given a new $36.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 3.2%
7/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 2.8%
5/20 Celcuity Announces Appointment of Leo Furcht to Board of Directors 2.1%
11/7 Q3/2019 9/30/2019 EPS -0.160 ZacksConsensus -0.180 ActVsEst 0.020 - Beat 1.9%
8/8 Celcuity Reports Second Quarter 2019 Financial Results 1.6%
1/13 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.5%
2/24 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.5%
5/20 Form 4 Celcuity Inc. For: May 16 Filed by: NIGON RICHARD 1.4%
4/23 Celcuity Inc. Schedules Release of First Quarter 2020 Financial Results and Conference Call 7.6%
5/8 Celcuity Inc (NASDAQ: CELC) was given a new $36.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 3.2%
7/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 2.8%
5/20 Celcuity Announces Appointment of Leo Furcht to Board of Directors 2.1%
11/7 Q3/2019 9/30/2019 EPS -0.160 ZacksConsensus -0.180 ActVsEst 0.020 - Beat 1.9%
8/8 Celcuity Reports Second Quarter 2019 Financial Results 1.6%
1/13 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.5%
2/24 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.5%
5/20 Form 4 Celcuity Inc. For: May 16 Filed by: NIGON RICHARD 1.4%
TOP News Decliners
2/14
Form SC 13G/A Celcuity Inc. Filed by: Sullivan Brian F.
-5.1%
8/1 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock. -4.3%
3/13 Celcuity Inc (NASDAQ: CELC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, down previously from $36.00. -3.6%
10/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -3.3%
8/10 Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -1.9%
11/20 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -1.1%
7/25 Celcuity Inc. Schedules Release of Second Quarter 2019 Financial Results and Conference Call -1.1%
12/11 Celcuity Presents Results at the 2019 San Antonio Breast Cancer Symposium Evaluating a Sub-Group of PIK3CA WT Breast Cancer Patients Who Have Hyperactive Signaling Tumors Responsive to PI3K Inhibitors -0.9%
11/11 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/27 Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2019 Financial Results and Conference Call -0.7%
8/1 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock. -4.3%
3/13 Celcuity Inc (NASDAQ: CELC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, down previously from $36.00. -3.6%
10/9 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -3.3%
8/10 Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -1.9%
11/20 Celcuity Inc (NASDAQ: CELC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -1.1%
7/25 Celcuity Inc. Schedules Release of Second Quarter 2019 Financial Results and Conference Call -1.1%
12/11 Celcuity Presents Results at the 2019 San Antonio Breast Cancer Symposium Evaluating a Sub-Group of PIK3CA WT Breast Cancer Patients Who Have Hyperactive Signaling Tumors Responsive to PI3K Inhibitors -0.9%
11/11 Celcuity Inc (NASDAQ: CELC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.8%
2/27 Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2019 Financial Results and Conference Call -0.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: